Following the identification of the inflammatory chemokine CXCL9 as the strongest participant in the inflammatory ageing clock and in cardiac and vascular dysfunction, in our previous studies we showed the possible role of CXCL9 and its receptor, CXCR3, in the occurrence of cardiovascular disorders in rheumatoid arthritis patients [35,36,38]. This evidence concerns the gene CXCL9 and cardiovascular disorder.